ABSTRACT
OBJECTIVE: To assess the risk of acute cardiactoxicity associated with anthracyclines use in patients with breast cancer and investigate the influencing factors on acute cardiactoxicity. METHODS: Cross-sectional analysis was carried out for 213 inpatients with breast cancer who received chemotherapy. RESULTS: ECG changes occurred in 37% patients. It was estimated that the incidence of acute cardiactoxicity associated with anthracyclines was about 30%. The main risk factors of acute cardiactoxicity were previous chemotherapy or radiotherapy, relative higher age(≥55), and menopause. CONCLUSION: ECG is an effective examination method for the patients who have acute cardiactoxicity reactions associated with anthracyclines. Clinical pharmacists should give more pharmaceutical care to post-menopause patients who have previously received chemotherapy or radiotherapy and are relatively old(≥55 years).